Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Deffered Revenue (2016 - 2018)

ImmunityBio (IBRX) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $2.7 million as the latest value for Q4 2018.

  • Quarterly Non-Current Deffered Revenue fell 17.62% to $2.7 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2018, down 17.62% year-over-year, with the annual reading at $2.7 million for FY2018, 17.62% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2018 was $2.7 million at ImmunityBio, down from $2.9 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $3.6 million in Q2 2017, with the low at $3000.0 in Q2 2015.
  • Average Non-Current Deffered Revenue over 5 years is $1.7 million, with a median of $1.5 million recorded in 2014.
  • The sharpest move saw Non-Current Deffered Revenue crashed 56.24% in 2015, then surged 6466.67% in 2016.
  • Over 5 years, Non-Current Deffered Revenue stood at $521000.0 in 2014, then crashed by 56.24% to $228000.0 in 2015, then surged by 964.04% to $2.4 million in 2016, then surged by 37.06% to $3.3 million in 2017, then fell by 17.62% to $2.7 million in 2018.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $2.7 million, $2.9 million, and $3.0 million for Q4 2018, Q3 2018, and Q2 2018 respectively.